Healthcare Sales & Marketing Network News: E7389

Searching News Database: E7389

HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Mar 2010
Eisai Submits Marketing Authorisation Application for Approval of Eribulin Mesylate in Europe, Based on Significant Overall Survival in Late Stage Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Biopharmacetuicals Onocology

HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Mar 2007
Eisai To Acquire Morphotek
Biopharmaceuticals Mergers & Acquisitions

Return to NewsFeed

Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 1 additional stories matching:
E7389
(Password required)

FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!